 Celldex Therapeutics, Inc. Celldex or the Company CLDX, today announced the closing of its underwritten public offering of 15,384,614 shares including 2,006,688 shares sold pursuant to the full exercise of the underwriters option to purchase additional shares of its common stock, par value 0.001 per share. All of the common stock was sold at a public offering price of 9.75 per share for total gross proceeds to Celldex of approximately 150.0 million, before deducting underwriting discounts and commissions and other offering expenses. With the closing of this offering, Celldex believes that the cash, cash equivalents and marketable securities at June 18, 2020 are sufficient to meet estimated working capital requirements and fund currently planned operations through 2023. 